Altimmune
ALT
47 hedge funds and large institutions have $61.7M invested in Altimmune in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 4 reducing their positions, and 7 closing their positions.
375% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 4
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
49% more capital invested
Capital invested by funds: $41.4M → $61.7M (+$20.3M)
31% more funds holding
Funds holding: 36 → 47 (+11)
8% more call options, than puts
Call options by funds: $151K | Put options by funds: $140K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.37M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.29M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.29M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.07M |
| 5 |
NRCM
Northern Right Capital Management
Darien,
Connecticut
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$3.4M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.44M |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$205K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$24K |
| 5 |
LPL Financial
San Diego,
California
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| – | -$7K | -12 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$4K | -7 | Closed |
|
53
Barclays
London,
United Kingdom
| – | -$1K | -5 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -3 | Closed |
|
ALT Hedge Fund Activity: Q2 2016 in Review
47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2016, worth a combined $61.7M — up 49% from $41.4M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ALT positions and 7 closed out — a net gain of 11 holders — while 19 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $3.37M. The largest seller was Visium Asset Management, exiting entirely with an estimated $3.4M sold.
- 47 institutional investors held Altimmune (ALT) as of Q2 2016, up from 36 in Q1 2016.
- Funds reported $61.7M of Altimmune stock for Q2 2016, up 49% quarter-over-quarter.
- 18 funds opened new Altimmune positions in Q2 2016 and 7 closed out, a net change of +11 holders.
- The largest Altimmune buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $3.37M added.
- The largest Altimmune seller in Q2 2016 was Visium Asset Management, an estimated $3.4M sold.
Based on aggregated 13F filings for Q2 2016.